Payment overview · 2025
General Payments
$448.03
13 reported records · 6 companies
Healthcare provider profile · identity verified
Alfredo Lopez, MD
Allopathic & Osteopathic Physicians|Family Medicine · MCALLEN, TX · NPI 1750307831
Verified facts
What the public records show
CMS Open Payments records show Alfredo Lopez, MD received $448.03 in general payments during 2025 across 13 reported records.
AstraZeneca Pharmaceuticals LP accounted for 40.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 282 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 218 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 374 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 434 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $180.46 | 40.3% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $174.05 | 38.9% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $30.00 | 6.7% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $27.50 | 6.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $22.49 | 5.0% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $13.53 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $448.03 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $174.05 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $54.11 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $41.66 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $33.86 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $30.00 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $27.50 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $22.49 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $13.53 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 282 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 374 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 434 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 83 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
122 | 47 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
282 | 75 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
218 | 54 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
374 | 72 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
110 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
434 | 83 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
83 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 919 | 298 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 752 | 259 |
| Metformin Hcl | Metformin Hcl | 685 | 215 |
| Losartan Potassium | Losartan Potassium | 620 | 184 |
| Levothyroxine Sodium | Levothyroxine Sodium | 578 | 159 |
| Amlodipine Besylate | Amlodipine Besylate | 574 | 177 |
| Gabapentin | Gabapentin | 479 | 160 |
| Omeprazole | Omeprazole | 470 | 175 |
| Metoprolol Succinate | Metoprolol Succinate | 442 | 147 |
| Ozempic | Semaglutide | 434 | 83 |
| Azithromycin | Azithromycin | 409 | 263 |
| Mounjaro | Tirzepatide | 374 | 72 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 345 | 116 |
| Farxiga | Dapagliflozin Propanediol | 282 | 75 |
| Baclofen | Baclofen | 258 | 107 |
| Tamsulosin Hcl | Tamsulosin Hcl | 246 | 83 |
| Montelukast Sodium | Montelukast Sodium | 240 | 79 |
| Fluticasone Propionate | Fluticasone Propionate | 239 | 132 |
| Alprazolam | Alprazolam | 237 | 48 |
| Alendronate Sodium | Alendronate Sodium | 233 | 84 |
| Tramadol Hcl | Tramadol Hcl | 226 | 69 |
| Donepezil Hcl | Donepezil Hcl | 223 | 61 |
| Ibuprofen | Ibuprofen | 223 | 96 |
| Diclofenac Sodium | Diclofenac Sodium | 218 | 99 |
| Jardiance | Empagliflozin | 218 | 54 |
| Escitalopram Oxalate | Escitalopram Oxalate | 213 | 63 |
| Lisinopril | Lisinopril | 209 | 60 |
| Meloxicam | Meloxicam | 198 | 92 |
| Meclizine Hcl | Meclizine Hcl | 196 | 87 |
| Furosemide | Furosemide | 193 | 87 |
| Januvia | Sitagliptin Phosphate | 173 | 46 |
| Pantoprazole Sodium | Pantoprazole Sodium | 169 | 63 |
| Metoprolol Tartrate | Metoprolol Tartrate | 161 | 45 |
| Trazodone Hcl | Trazodone Hcl | 158 | 58 |
| Clopidogrel | Clopidogrel Bisulfate | 157 | 40 |
| Cilostazol | Cilostazol | 154 | 51 |
| Ezetimibe | Ezetimibe | 152 | 52 |
| Vascepa | Icosapent Ethyl | 146 | 67 |
| Myrbetriq | Mirabegron | 143 | 45 |
| Mupirocin | Mupirocin | 142 | 99 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 137 | 93 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 132 | 60 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 125 | 40 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 124 | 67 |
| Hydralazine Hcl | Hydralazine Hcl | 122 | 47 |
| Linzess | Linaclotide | 122 | 47 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 121 | 44 |
| Pravastatin Sodium | Pravastatin Sodium | 120 | 30 |
| Potassium Chloride | Potassium Chloride | 119 | 49 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 118 | 27 |
| Lorazepam | Lorazepam | 118 | 22 |
| Ondansetron Hcl | Ondansetron Hcl | 118 | 60 |
| Memantine Hcl | Memantine Hcl | 117 | 32 |
| Finasteride | Finasteride | 114 | 35 |
| Trulicity | Dulaglutide | 110 | 17 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 107 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 105 | 43 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 105 | 34 |
| Zolpidem Tartrate | Zolpidem Tartrate | 104 | 25 |
| Pioglitazone Hcl | Pioglitazone Hcl | 101 | 30 |
| Carvedilol | Carvedilol | 100 | 30 |
| Levofloxacin | Levofloxacin | 98 | 77 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 98 | 73 |
| Famotidine | Famotidine | 97 | 40 |
| Celecoxib | Celecoxib | 96 | 56 |
| Cephalexin | Cephalexin | 96 | 86 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 95 | 54 |
| Naproxen | Naproxen | 93 | 47 |
| Clonidine Hcl | Clonidine Hcl | 90 | 27 |
| Simvastatin | Simvastatin | 89 | 31 |
| Nifedipine Er | Nifedipine | 83 | 28 |
| Rybelsus | Semaglutide | 83 | 22 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 83 | 72 |
| Cefdinir | Cefdinir | 82 | 72 |
| Xarelto | Rivaroxaban | 81 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 79 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 78 | 22 |
| Tradjenta | Linagliptin | 76 | 25 |
| Pregabalin | Pregabalin | 73 | 18 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 72 | 55 |
| Glipizide | Glipizide | 70 | 21 |
| Icosapent Ethyl | Icosapent Ethyl | 69 | 30 |
| Allopurinol | Allopurinol | 65 | 22 |
| Dicyclomine Hcl | Dicyclomine Hcl | 64 | 36 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 63 | 25 |
| Paxlovid | Nirmatrelvir/Ritonavir | 61 | 60 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 60 | 14 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 59 | 29 |
| Sertraline Hcl | Sertraline Hcl | 58 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 58 | 19 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 56 | 36 |
| Ketoconazole | Ketoconazole | 53 | 22 |
| Sucralfate | Sucralfate | 52 | 28 |
| Clindamycin Hcl | Clindamycin Hcl | 50 | 44 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 49 | 47 |
| Fluconazole | Fluconazole | 49 | 30 |
| Valacyclovir | Valacyclovir Hcl | 49 | 30 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 48 | 15 |
| Eliquis | Apixaban | 47 | 19 |
| Clonazepam | Clonazepam | 46 | suppressed |
| Repaglinide | Repaglinide | 46 | 14 |
| Buspirone Hcl | Buspirone Hcl | 45 | suppressed |
| Entresto | Sacubitril/Valsartan | 45 | 17 |
| Ofloxacin | Ofloxacin | 45 | 42 |
| Tresiba Flextouch U-100 | Insulin Degludec | 45 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | 17 |
| Prednisone | Prednisone | 44 | 36 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 40 | 11 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 40 | suppressed |
| Levetiracetam | Levetiracetam | 40 | 11 |
| Hydrocortisone | Hydrocortisone | 39 | 30 |
| Ropinirole Hcl | Ropinirole Hcl | 39 | 13 |
| Spironolactone | Spironolactone | 37 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 36 | suppressed |
| Nitroglycerin | Nitroglycerin | 36 | 21 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 34 | 13 |
| Irbesartan | Irbesartan | 34 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 34 | 11 |
| Ciclopirox | Ciclopirox | 33 | 17 |
| Gemtesa | Vibegron | 33 | 14 |
| Lactulose | Lactulose | 33 | 20 |
| Valsartan | Valsartan | 33 | 11 |
| Dapagliflozin | Dapagliflozin Propanediol | 32 | 22 |
| Tresiba Flextouch U-200 | Insulin Degludec | 32 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 30 | 15 |
| Clotrimazole | Clotrimazole | 30 | 21 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | 15 |
| Ventolin Hfa | Albuterol Sulfate | 30 | 13 |
| Atenolol | Atenolol | 29 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 29 | suppressed |
| Lansoprazole | Lansoprazole | 29 | 13 |
| Gemfibrozil | Gemfibrozil | 28 | 11 |
| Memantine Hcl Er | Memantine Hcl | 28 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 28 | suppressed |
| Prolia | Denosumab | 28 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 27 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 27 | 12 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 27 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 26 | suppressed |
| Terconazole | Terconazole | 26 | 22 |
| Bupropion Hcl Sr | Bupropion Hcl | 24 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 24 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 24 | 12 |
| Amoxicillin | Amoxicillin | 23 | 15 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Mirtazapine | Mirtazapine | 23 | suppressed |
| Primidone | Primidone | 23 | suppressed |
| Bumetanide | Bumetanide | 22 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 21 | suppressed |
| Methylprednisolone | Methylprednisolone | 21 | 14 |
| Midodrine Hcl | Midodrine Hcl | 21 | 11 |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 21 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Rexulti | Brexpiprazole | 21 | suppressed |
| Latanoprost | Latanoprost | 20 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 20 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 20 | 19 |
| Solifenacin Succinate | Solifenacin Succinate | 20 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 19 | 18 |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 19 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 19 | suppressed |
| Olanzapine | Olanzapine | 19 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 19 | suppressed |
| Sulfasalazine | Sulfasalazine | 19 | suppressed |
| Synthroid | Levothyroxine Sodium | 19 | suppressed |
| Torsemide | Torsemide | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Telmisartan | Telmisartan | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Constulose | Lactulose | 16 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 15 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 15 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 15 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 15 | suppressed |
| Belsomra | Suvorexant | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | 12 |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 13 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 13 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 13 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 12 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $448.03 · 13 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, FARXIGA, JOURNAVX, MOUNJARO, Ozempic, Rybelsus, VRAYLAR, XIFAXAN | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error